RARRES2 and melanoma: Downregulation of chemerin expression was described in many cancers, including non-small-cell lung carcinoma (NSCLC) [7], squamous cell carcinoma of the skin [6], and melanoma [8], and such downregulation was often associated with poor clinical outcomes.